Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorLecour, Sandrine
dc.contributor.authorAndreadou, Ioanna
dc.contributor.authorBøtker, Hans Erik
dc.contributor.authorDavidson, Sean M
dc.contributor.authorHeusch, Gerd
dc.contributor.authorRuiz Meana, Marisol
dc.date.accessioned2022-06-13T13:21:41Z
dc.date.available2022-06-13T13:21:41Z
dc.date.issued2021-09-13
dc.identifier.citationLecour S, Andreadou I, Bøtker HE, Davidson SM, Heusch G, Ruiz-Meana M, et al. IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action. Basic Res Cardiol. 2021 Sep 13;116:52.
dc.identifier.issn1435-1803
dc.identifier.urihttp://hdl.handle.net/11351/7674
dc.descriptionCardioprotection; Drug development; Infarction
dc.description.abstractAcute myocardial infarction (AMI) and the heart failure (HF) which may follow are among the leading causes of death and disability worldwide. As such, new therapeutic interventions are still needed to protect the heart against acute ischemia/reperfusion injury to reduce myocardial infarct size and prevent the onset of HF in patients presenting with AMI. However, the clinical translation of cardioprotective interventions that have proven to be beneficial in preclinical animal studies, has been challenging. One likely major reason for this failure to translate cardioprotection into patient benefit is the lack of rigorous and systematic in vivo preclinical assessment of the efficacy of promising cardioprotective interventions prior to their clinical evaluation. To address this, we propose an in vivo set of step-by-step criteria for IMproving Preclinical Assessment of Cardioprotective Therapies (‘IMPACT’), for investigators to consider adopting before embarking on clinical studies, the aim of which is to improve the likelihood of translating novel cardioprotective interventions into the clinical setting for patient benefit.
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofseriesBasic Research in Cardiology;116
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectReperfusió miocardíaca
dc.subjectCor - Malalties - Tractament
dc.subjectCor - Malalties - Prevenció
dc.subject.meshMyocardial Infarction
dc.subject.mesh/prevention & control
dc.subject.meshReperfusion Injury
dc.titleIMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1007/s00395-021-00893-5
dc.subject.decsinfarto de miocardio
dc.subject.decs/prevención & control
dc.subject.decsdaño por reperfusión
dc.relation.publishversionhttps://doi.org/10.1007/s00395-021-00893-5
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Lecour S] Department of Medicine, Hatter Institute for Cardiovascular Research in Africa, University of Cape Town, Cape Town, South Africa. [Andreadou I] Laboratory of Pharmacology, Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece. [Bøtker HE] Department of Cardiology, Aarhus University Hospital, Aarhus N, Denmark. [Davidson SM] The Hatter Cardiovascular Institute, University College London, London, UK. [Heusch G] Institute for Pathophysiology, West German Heart and Vascular Center, University of Duisburg-Essen, Essen, Germany. [Ruiz-Meana M] Grup de Recerca en Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid34515837
dc.identifier.wos000698137400001
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2017-2020/PI19%2F01196
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record